LZ-Max Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, preventing bronchoconstriction, inflammation, and mucus production associated with allergic responses. The synergistic action of these agents provides comprehensive relief from both immediate and late-phase allergic symptoms. LZ-Max is indicated for patients requiring effective control of seasonal and perennial allergic rhinitis and for adjunctive therapy in asthma management, particularly in patients with concomitant allergic rhinitis. The recommended dosage is one tablet once daily, preferably in the evening, with or without food. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to any component. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. LZ-Max should be used under medical supervision, with consideration of patient history and potential drug interactions to ensure optimal therapeutic outcomes.